IRulya Therapeutics Inc.
Nasdaq IRLA · New Haven, CT
Works in Hematology · Immunology
IRulya Therapeutics Inc. is a clinical trial sponsor based in New Haven, CT, listed as Nasdaq IRLA. It has 1 active clinical trial with 60 planned participants, in Hematology and Immunology.
Trial track record · since 2021
Financials · Nasdaq IRLA
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about IRulya Therapeutics Inc
IRulya Therapeutics Inc is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 60 planned participants, in Hematology, Immunology. Since 2021 it has completed 0 trials and stopped 0 early.
IRulya Therapeutics Inc is based in New Haven, CT and is listed as Nasdaq IRLA. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with IRulya Therapeutics Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-21.
Approve Suite is not affiliated with IRulya Therapeutics Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.